{"id":"891847325413-63","name":"Ludger Ltd","registrationDate":"2017-01-12T15:02:18.440+01:00","category":2,"subCategory":3,"legal":"Private Limited Company (UK Company No 3803367)","web":"http://www.ludger.com","country":"United kingdom","headAddress":"Ludger Ltd","headCity":"Oxfordshire","headPostCode":"OX14 3EB","headPhone":"(44)18 65 40 85 54","boss":"Daryl Fernandes","bossTitle":"Mr","bossPosition":"Chief Executive","membersCount":6,"membersFTE":"2.0","membership":"OBN (http://www.obn.org.uk/)&#xd;\n&#xd;\nMediwales (http://www.mediwales.com/)&#xd;\n&#xd;\nConsortia (EU-funded programmes and training networks):&#xd;\nGlySign (http://www.glysign.eu/)&#xd;\nGlyCoCan (https://glycocan.eu/)&#xd;\nGlycoPar (http://www.glycopar.eu/)&#xd;\nIBDBIOM (http://www.ibdbiom.eu/)&#xd;\nHighGlycan (http://www.highglycan.eu/)","memberOrga":"","goal":"Ludger is a UK bioscience SME specialising in glycomics for healthcare. It was founded in 1999 by CEO Dr Daryl Fernandes and has labs at the Culham Science Centre and an office in Shanghai. Our main focus is on patient stratification in inflammatory conditions, cancers and cardiovascular diseases. &#xd;<br />Main activities:&#xd;<br /> 1: Services for biopharma to support regulatory submissions.&#xd;<br /> 2: Products for drug development.&#xd;<br /> 3: Funded collaborations in medical research.&#xd;<br /> 4: Active R&amp;D programme for development of novel glycomics technologies to support biopharmaceutical realisation and Precision Medicine. &#xd;<br />&#xd;<br />Our main clients are developers and producers of glycoprotein therapeutics. We have sales territories in USA, UK, Europe, India, China, Japan, Korea and Singapore.&#xd;<br />&#xd;<br />We intend to greatly expand our commercial operations over the next decade.","acronym":"Ludger Ltd","interests":"Culture, Development, Economic and Financial Affairs, Education, Employment and Social Affairs, Information Society, Public Health","euInitiatives":"We will be visiting Luxembourg to have meetings with various EU Institutions and agencies and intend to apply under H2020 Funding to support efforts to build an informatics system to support the development of new precision medicine workflows for people with diabetes.","lastUp":"2018-01-14T16:48:39.267+01:00","customers":"","costAbsolu":"","costRange":"50000-99999","turnoverAbsolu":0,"turnoverRange":""}